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Abstract: Previous reports indicate that over 13 different tumors, including hepatocellular 
carcinoma (HCC), are related to obesity. Obesity-associated inflammatory, metabolic, and endo-
crine mediators, as well as the functioning of the gut microbiota, are suspected to contribute to 
tumorigenesis. In obese people, proinflammatory cytokines/chemokines including tumor necrosis 
factor-alpha, interleukin (IL)-1 and IL-6, insulin and insulin-like growth factors, adipokines, 
plasminogen activator inhibitor-1, adiponectin, and leptin are found to play crucial roles in the 
initiation and development of cancer. The cytokines induced by leptin in adipose tissue or tumor 
cells have been intensely studied. Leptin-induced signaling pathways are critical for biological 
functions such as adiposity, energy balance, endocrine function, immune reaction, and angio-
genesis as well as oncogenesis. Leptin is an activator of cell proliferation and anti-apoptosis 
in several cell types, and an inducer of cancer stem cells; its critical roles in tumorigenesis are 
based on its oncogenic, mitogenic, proinflammatory, and pro-angiogenic actions. This review 
provides an update of the pathological effects of leptin signaling with special emphasis on 
potential molecular mechanisms and therapeutic targeting, which could potentially be used in 
future clinical settings. In addition, leptin-induced angiogenic ability and molecular mechanisms 
in HCC are discussed. The stringent binding affinity of leptin and its receptor Ob-R, as well as 
the highly upregulated expression of both leptin and Ob-R in cancer cells compared to normal 
cells, makes leptin an ideal drug target for the prevention and treatment of HCC, especially in 
obese patients.
Keywords: hepatocellular carcinoma, leptin, leptin antagonist, leptin signaling, tumor angio-
genesis, drug target
Introduction
It has been reported that over 400 million people are obese worldwide, and the 
number is projected to reach 700 million by 2015.1 According to the reports from 
the International Association for the Study of Obesity, approximately one-fourth of 
European men and women are obese and approximately one-half of European men 
and one-third of European women are overweight.2 In the United States, where adult 
obesity is 30%–35%, the obesity epidemic also poses threats to public health.3–6 The 
escalation of obesity and overweight has become a global problem in the past decade. 
Accumulating evidence indicates that the obese state shares some characteristics with 
chronic low-grade inflammation, which deliberates various diseases, particularly 
cardiovascular disease,7,8 chronic kidney disease,9–11 dyslipidemia,12 hypertension,13,14 
liver disease,15–17 type 2 diabetes,18 as well as a number of tumors.19–21 Many tumors, 
including gynecologic tumors (breast, ovarian, cervical, uterine cancer), digestive 
system tumors (esophageal, stomach, colon or rectal, liver, gall bladder, pancreatic), 
and hematologic tumors (multiple myeloma and non-Hodgkin lymphoma), as well 
as others, such as kidney and glioma, are found to be correlated with obesity.19,20,22–24 
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It is estimated that being overweight or obese contributes to 
20% of cancer deaths in the United States.25
Although obesity has been considered as an increased risk 
for many cancers, the molecular mechanisms by which obesity 
affects cancer incidence is still unclear. Obesity-associated 
inflammatory, metabolic, and endocrine mediators, as well 
as the functioning of the gut microbiota, are suspected to 
contribute to tumorigenesis. Among obese people, proin-
flammatory cytokines/chemokines including tumor necrosis 
factor-alpha (TNF-α), interleukin (IL)-1, IL-6, insulin and 
insulin-like growth factors (IGFs), adipokines, plasminogen 
activator inhibitor-1, adiponectin, and leptin are found to play 
a crucial role in the initiation and development of cancer.26–30 
The gut microbiota, including altered microbial metabolism, 
is able to contribute to the generation of procarcinogenic 
toxic metabolites; increased extraction of energy and nutrient 
availability leading to metabolic dysregulation contributes 
to tumor initiation and progression.31–33 Among the above 
molecules, leptin is the most abundant adipokine. Since it was 
first cloned in 1994,34 this cytokine-like hormone, controlling 
adipocyte mass and energy balance by binding to the leptin 
receptor (Ob-R), has been the subject of intensive studies in 
cancer development.
Hepatocellular carcinoma (HCC) is the most typical liver 
cancer. Approximately three-quarters of total liver cancer 
worldwide are associated with HCC, which is the major 
histological subtype of liver cancer burden worldwide, and 
complicating cirrhosis due to chronic viral infection or toxic 
injury remains the third leading cause of cancer death in the 
world. HCC is increasingly diagnosed among individuals 
with obesity and related disorders. A systematic review and 
meta-analysis, along with other evidences, linked obesity to 
increased risk of common and less common malignancies, 
such as HCC.35 A number of epidemiological studies have 
reported that overweight and/or obesity are associated with a 
greater risk of HCC compared to the general population.36–39 
A significant increase in serum leptin levels and a posi-
tive correlation between the serum levels of leptin and 
α-fetoprotein in cirrhotic HCC group were also observed in 
HCC patients.40 The serum leptin levels were also found to 
be considerably higher in patients with HCC than in normal 
healthy controls in another study.41
In light of the increasingly reported role of leptin in sev-
eral types of cancer,42–47 this review is focused on the updated 
knowledge on the oncogenic role of leptin signaling in the 
occurrence and development of HCC, clinical significance, 
and development of specific drug targets in HCC. Addi-
tionally, leptin-induced angiogenic ability and molecular 
mechanisms in HCC cells are also discussed. The stringent 
binding affinity of leptin/Ob-R, the overexpression of leptin/
Ob-R, and its targets in cancer cells make leptin a unique drug 
target for the prevention and treatment of HCC, particularly 
in obese patients.
Cellular and molecular structure 
and function of leptin and the leptin 
receptor
Leptin, coded by the LEP gene, is a small, 167-amino acid, 
nonglycosylated protein. The name of “leptin” is derived from 
the Greek word “leptos,” which means “thin”. The biological 
function of leptin in energy homeostasis was determined by 
normalization of hyperphagy and obese phenotypes using 
recombinant leptin administration in rodents and humans.48,49 
Leptin also plays critical roles in the regulation of immune 
response, growth, reproduction, glucose homeostasis, and 
angiogenesis.50–53 The N-terminal region (94 amino acids) in 
leptin protein is essential for both its biological and receptor 
binding activities.54 The binding of leptin to Ob-R is capable 
of inducing the extracellular domains of Ob-R to form a 
homodimer, which constitutes the functional unit responsible 
for leptin-mediated signals.
Ob-R belongs to a member of the class I cytokine receptor 
superfamily.55 This superfamily of receptors needs auxiliary 
kinases for activation because they lack autophosphorylation 
capabilities. So far, six leptin receptor isoforms generated by 
mRNA alternative splicing have been discovered56: shorter 
isoforms with less biological activity (OB-RS) and the long 
isoform (OB-RL or OB-Rb) with full intracellular signaling 
capabilities.47,55 All Ob-R forms have the common large 
extracellular domain of Ob-R (816 amino acids).47 In con-
trast, all Ob-R forms have variable lengths of cytoplasmatic 
tail (300 amino acid residues).57,58 Ob-R binding to leptin 
induces its conformational changes that recruit Janus kinases 
(JAKs), which in turn phosphorylate Ob-R and activate signal 
transducers and activators of transcription (STATs).47 In addi-
tion to the JAK2/STATs signaling pathway, leptin binding 
to Ob-R also induces canonical (phosphoinositide 3-kinase 
[PI-3K]/protein kinase B [Akt], mitogen-activated protein 
kinase [MAPK]/extracellular regulated kinase 1 and 2 [ERK 
1/2]), and noncanonical signaling pathways (AMPK, JNK, 
PKC, and p38 MAPK) in diverse cell types. The long form 
(Ob-Rb) has a long intracellular domain which is essential 
for intracellular signal transduction. Only Ob-Rb in the leptin 
receptor isoforms contains an intact intracellular domain 
and has the ability to activate the intracellular JAK/STAT 
pathway on ligand binding.47,59 Importantly, leptin-mediated Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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STAT3 (signal transducer and activator of transcription 3) 
signaling needs Tyr-1138 of Ob-Rb for its action.60–62 In 
addition, leptin-induced signals occur in normal peripheral 
tissues, but the high level of leptin in obesity could amplify 
leptin signaling, thereby finally inducing the development of 
obesity-associated cancers.
Expression of leptin and Ob-R  
in human HCC
Wang et al63 examined, using immunohistochemical stain-
ing, leptin expression in 36 cases of adjacent nontumorous 
liver tissues (36/36, 100%) with moderate (++) to strong 
(+++) intensity and in 72.22% (26/36) of HCC with weaker 
(+) intensity (P0.05). However, they suggested that further 
studies were needed to determine the inhibitory and/or activat-
ing role of leptin in the etiology, carcinogenesis, and progress 
of human HCC.63 In another report,64 high leptin expression 
was demonstrated in 60.3% of patients with HCC and was 
not correlated to Ki-67 expression, but it is significantly cor-
related to intratumor microvessel density (high vs low; 59.2 
[standard deviation 3.2] vs 44.2 [19.5], P=0.004). However, 
leptin expression was determined as a predictor for improved 
overall survival of patients with HCC (odds ratio [OR] 0.16; 
95% confidence interval [CI] 0.03–0.87; P=0.033) using a 
multivariate Cox’s proportional hazards model. Interestingly, 
high Ob-R expression was detected in 53% of HCC patients 
and was also significantly correlated to intratumor microvessel 
density (high vs low; 59.4 [3.2] vs 44.7 [3.7]; P=0.004).64 In 
addition, high Ob-R expression was associated with a better 
overall survival (P=0.027) using the Kaplan–Meier survival 
curve.64 Multivariate analysis also showed that Ob-R expres-
sion was a significant determinant for HCC (OR 0.02, 95% CI 
0.01–0.85; P=0.041).64 In a recent study,65 the overexpression 
rate of leptin and Ob-R in 81 HCC patients was 56.8% and 
35.8%, respectively. Ob-R overexpression was significantly 
correlated to the tumor size and TNM stage (P0.05), but not 
to age, body mass index, α-fetoprotein, hepatitis B surface 
antigen status, tumor grade, vascular invasion, or liver cirrhosis 
(P0.05). Leptin overexpression showed no significant cor-
relations to the above clinicopathological factors (P0.05). In 
vitro, leptin and Ob-R are simultaneously expressed in the HCC 
cell line HepG2.66 Leptin increased HepG2 cell proliferation 
in a concentration- and time-dependent manner. The effect of 
promotion of cell proliferation by leptin is due to the increment 
of DNA synthesis and enhancement of mitotic activity.
The results of the previous studies were inconsistent and 
contradictory. The existing conflicts among different studies 
might be due to the use of different tools or different stages 
of tumor tissues. Therefore, leptin may be involved in the 
occurrence and development of HCC, and the specific role 
and mechanism needs further research.
Interaction between leptin signaling 
and oncogenic pathways in HCC
In the central nervous system, particularly in the hypothalamus, 
which is a site of high Ob-Rb mRNA expression, many of 
the effects are attributable to leptin. Alternative splicing and 
proteolytic cleavage events also produce a circulating extra-
cellular domain of Ob-R, which may affect the stability of 
circulating leptin.47,51 The cell-membrane-bound short-form 
receptors may also have potentially important roles, including 
the endocytosis and transport of leptin across the blood–brain 
barrier. High levels of leptin in obese patients are not able to 
suppress feeding and decrease body weight (BW)/adiposity. 
The proposed mechanisms of leptin resistance include pertur-
bations in developmental programming, alterations in cellular 
Ob-Rb signaling, alterations in the transport of leptin across 
the blood–brain barrier, and others.67 In peripheral tissues, 
high levels of circulating leptin could also overregulate the 
signaling and expression of active Ob-R. These phenomena 
lead to the deregulation of leptin signaling, thereby signifi-
cantly contributing to HCC progression through its crosstalk 
with multiple signaling pathways, as discussed in breast 
cancer47or colorectal cancer.68
The PI-3K/Akt pathway, an assembly of membrane-
localized complexes, plays a central role in a variety of mul-
tiple biological processes such as cell motility, proliferation, 
survival, and angiogenesis in tumor cells including HCC.69–72 
The PI-3K/Akt pathway also plays a major role in tumor 
growth factor (TGF)-β-induced epithelial–mesenchymal 
transformation (EMT), notably through the regulation of 
translation and cell invasion during carcinogenesis.73,74 In 
addition, many of the transforming events in HCC are a 
result of the enhancement or deregulation of PI3-K/Akt 
pathway.72,75 A great number of studies have already estab-
lished the central role of leptin-induced regulation of the 
PI-3K/Akt signaling pathway in several types of cancer 
including HCC (Figure 1).47,76–85
Mounting evidence has shown that the STAT3 is a fre-
quent biochemical aberrant in the development, progression, 
and maintenance of cancer cells.86,87 STAT3 regulates a 
variety of genes involved in the regulation of critical func-
tions, including immune responses, cell proliferation, dif-
ferentiation, angiogenesis, apoptosis, and metastasis. STAT3 
can function either as an oncoprotein or a tumor suppressor 
depending on the specific genetic background or in different Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 1 Crosstalk between leptin signaling and signaling pathways in HCC.
Notes: Leptin binding to the receptor Ob-R in HCC cells activates canonical (JAK2/STAT, MAPK, and Pi-3K) signaling pathways. Leptin-induced JAK2/STAT3, MAPK, Pi-3K/
mTOR, p38, and JNK signaling. Pi-3K/Akt induces phosphorylation of mTOR. MAPK activation plays an important role in activating eRK 1/2, p38, and JNK, which in turn 
induce NF-κB activation. Levels of proinflammatory/pro-angiogenic molecules can also be induced by leptin signaling pathways. Solid and dashed arrows indicate the main 
and alternative mechanisms of leptin actions.
Abbreviations: HCC, hepatocellular carcinoma; JAK2, Janus kinase 2; MAPK, mitogen-activated protein kinase; Pi-3K, phosphoinositide 3-kinase; mTOR, mammalian target of 
rapamycin; Akt, protein kinase B; eRK 1/2, extracellular regulated kinase 1 and 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; STAT, signal trans  ducer 
and activator of transcription; Adip, adipose; Lep, leptin; eR, estrogen receptor.
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contexts of cancer biology.88 However, for many tumors, 
increased levels of activated STAT3 have been associated 
with worsened prognosis, indicating that STAT3 could be 
an attractive molecular target for the development of novel 
malignancy therapeutics.89,90
The STAT3 pathway mediates leptin actions on food 
intake, weight gain, glucose metabolism, and neuroendo-
crine function, but does not influence fertility and glycemic 
control.91 In malignant cells, the STAT3 pathway is involved 
in leptin actions in cell migration,85,92 proliferation,93–98 and 
anti-apoptosis.82,99,100 Leptin-STAT3 regulates the genes 
cyclooxygenase (COX)-2,83 cyclin D1 (kinase and regulator 
of cell cycle D1),93,95 human telomerase reverse transcriptase 
(hTERT),101 VEGF,102,103 leptin,102 and survivin.104 STAT3 could 
also regulate nuclear factor kappa-light-chain-enhancer of acti-
vated B cells,105,106 IL-1, Notch,107,108 canonical WNT,109,110 and 
VEGFR-2,107,108 and thereby regulate tumor angiogenesis.
Leptin could crosstalk with signaling pathways which 
are involved in the pathogenesis of nonalcoholic fatty liver 
disease, which is a risk disease of HCC.111–113 Leptin is able to 
contribute to the development of insulin resistance, steatosis, 
proinflammation, and liver fibrosis.46,114 Leptin injections 
have been shown to result in the increased expression of 
procollagen-I, TGF-β1, and smooth muscle actin which is a 
marker of activated hepatic stellate cells, and eventually to 
increased liver fibrosis.115
Leptin could also crosstalk with signaling pathways 
which involve in the development of fibrosis. Aleffi et al iden-
tified the effect of leptin on fibrogenic cells is the induction 
of vascular endothelial growth factor (VEGF) via oxygen-
independent activation of hypoxia-inducible factor 1a, 
which is a master switch of the angiogenic response.116 
Their results strongly suggest the fibrogenic role of leptin 
in the liver.Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
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Therapeutic potential for leptin/
Ob-R signaling molecules
Evidence ever more strongly implicates that leptin/Ob-R 
signaling is correlated to many cancer types and point toward 
new drug targets. Leptin binds only to Ob-R. Moreover, the 
extracellular activation of Ob-R is obtained only upon leptin 
binding to its extracellular region.47 Interestingly, this family of 
receptors is capable of binding only to leptin or leptin-modified 
peptides, indicating the potential use of leptin antagonists and/
or other inhibitors in blocking Ob-R signals.47,117
Previous studies have shown that blocking of leptin 
signaling could cause decreased growth and development 
of mammary tumors derived from mice and humans.118,119 
Tumor growth and the expression of VEGF-A/VEGFR-2 
were markedly reduced in orthotopic mouse models using 
a pegylated leptin peptide receptor antagonist (PEG-
LPrA2).118,119 The BW or appetite of a large number of 
normal lean (male and female) CD-1 and BALB/c mice did 
not change during a several months of using PEG-LPrA2. 
Surmacz’s group reported similar results in the same ortho-
tropic xenograft model using a different leptin antagonist 
(Allo-aca).120 Allo-aca induced 6%–10% BW increase, but it 
significantly extended the mouse survival time for 1–2 weeks 
and did not show systemic toxicity when tested for toxicity 
effects in normal CD-1 mice.120 Recently, the same group 
tested a number of Allo-aca analogs. d-Ser was a peptidom-
inetic and distributed only in the periphery of experimental 
animals. This novel peptide d-Ser may serve as a prototype 
to develop new therapeutics because it significantly inhibited 
leptin-dependent proliferation of Ob-R-positive cancer cells 
in vitro at 1 nM concentration without exhibiting any partial 
agonistic activity.121 The above results indicate that inhibition 
of leptin signaling by leptin antagonists may serve as a novel 
adjuvant for the treatment of HCC.
Several groups have developed antibodies targeting 
leptin signaling. Zabeau et al produced and evaluated a 
number of neutralizing nanobodies targeting Ob-R.122 Three 
classes of neutralizing nanobodies targeting different Ob-R 
subdomains, ie, the Ig-like and fibronectin type III domains 
and cytokine receptor homology 2, were identified. Among 
them, only nanobodies directed against the cytokine recep-
tor homology 2 domain inhibited leptin binding. Ross and 
Strasburger’s groups developed monoclonal antibodies 
(mAbs) against human Ob-R and verified their antagonistic 
activity using an LEP-signaling bioassay.123,124 9F8, the most 
promising mAb showed dose-dependent antagonist activity 
using the LEP bioassay. However, all the above-mentioned 
antibodies have not been used in cancer therapy.
In summary, although there have already been com-
pounds or antibodies targeting leptin/Ob-R that showed 
significant in vitro or in vivo anticancer effect, they have 
not been utilized in clinical settings. The major reason might 
be the low efficiency and specificity of some compounds or 
antibodies. In addition, the side effects of these drugs are not 
completely known and require further studies.
Conclusion
Obesity-associated inflammatory, metabolic, and endocrine 
mediators are suspected to play a role in tumorigenesis. Body 
fat and adipocyte size are clearly correlated to high leptin 
levels in obesity and in overweight individuals or popula-
tions. High leptin level is a hallmark of obesity, which has 
been correlated to the incidence and progression of several 
malignancies including HCC. In vitro studies have clearly 
demonstrated the role of leptin in HCC proliferation, migra-
tion, and angiogenesis. In addition, leptin signaling and its 
crosstalks with many signaling pathways, such as PI-3K/Akt 
and STAT3, play critical roles in HCC cell growth, invasion, 
angiogenesis, and metastasis. There are still a number of 
gaps to fill in the field of leptin signaling in HCC, especially 
further identification of the molecular mechanisms of leptin-
signaling-mediated regulation of HCC. There are conflicting 
data concerning the correlation between tissue leptin level 
and HCC risk. Although several groups have developed 
antibodies targeting leptin signaling, all these antibodies 
have not been used in cancer therapy. Novel opportunities 
could emerge from the discovery of leptin crosstalk with 
other oncogenic pathways, inflammatory and angiogenic 
cytokines, and their links to obesity-related cancers.
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